Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar jetlith (22.31) Submitted: 7/3/2008 10:40:03 PM : Underperform Start Price: $32.59 ACOR Score: +38.30

topped out

Featured Broker Partners


Advertisement